Filing summary
Entity and period: The provided filing identifies the registrant as Kintara Therapeutics, Inc. (Nasdaq: KTRA), not Tuhura Biosciences, Inc. It is a Form 10-Q for the three months ended September 30, 2023, Kintara’s fiscal first quarter. Financial statement amounts below are in U.S. dollars, in thousands, unless stated otherwise.
Business context and financial results
Kintara is a clinical-stage cancer drug developer. It reported no revenue and is dependent on external funding. During the quarter, its programs were VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer.
- Results: Net loss was $2.962 million, compared with $4.596 million in the prior-year quarter. Loss attributable to common stockholders was $3.137 million versus $4.960 million; basic and diluted loss per share was $1.83 versus $3.39.
- Expenses: Research and development was $1.859 million, down 41% from $3.171 million. General and administrative expense was $1.103 million, down 25% from $1.475 million. Management attributed the declines mainly to lower clinical development spending, share-based compensation, and personnel costs.
- Cash flow: Operating cash use was $1.317 million, compared with $6.369 million in the prior-year quarter. The current-period figure included a $1.075 million reduction in the clinical trial deposit. Investing cash flow was nil; financing cash flow was negative $2,000, reflecting a preferred dividend, with no share-sale proceeds in the quarter.
- Liquidity and balance sheet: Cash was $216,000 at September 30, down from $1.535 million at June 30. Working capital was negative $2.553 million, versus positive $188,000 at June 30. Total assets were $1.477 million, total liabilities $3.503 million, and stockholders’ equity was a deficit of $2.026 million.
- Obligations: Current liabilities were $3.336 million, including $2.998 million of accounts payable and accrued liabilities and $338,000 payable to related parties. The balance sheet lists a $167,000 milestone payment liability; it does not show a conventional borrowing balance.
Material changes, outlook, and risks
- Program shift after quarter-end: On October 31, 2023, Kintara reported preliminary GBM AGILE results showing VAL-083 did not perform better than glioblastoma standards of care, with preliminary safety similar to those standards. The company announced suspension of VAL-083 development and a focus on REM-001. It expected the full VAL-083 dataset around the end of the first quarter of calendar 2024.
- REM-001 funding and plans: Kintara received a $2.0 million NIH grant award for the REM-001 15-patient study, payable in tranches over two years as eligible expenses are incurred. The company said the program would restart and expected enrollment to begin in calendar Q4 2023. It reported receiving $13,000 of grant reimbursement in the quarter. Grant funding is subject to performance conditions and funding risk.
- Additional post-quarter financing: From October 31 through November 13, 2023, Kintara raised $968,000 net through its at-the-market facility. The facility permits up to $2.85 million in aggregate sales. The company also received stockholder approval on October 9 to issue 20% or more of its shares under its Lincoln Park purchase agreement.
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern within one year of the filing. Despite grant funding and financing arrangements, it said significant additional funding is required. Financing plans include equity sales, grant funding, and strategic partnerships; success is not assured. Failure to obtain funding could require delaying, reducing, or eliminating programs, or pursuing bankruptcy or dissolution.
- Other notable risks: Nasdaq notified Kintara on September 20, 2023 that it did not meet the $2.5 million stockholders’ equity requirement. The filing describes a deadline to submit a compliance plan but does not clearly state the subsequent resolution. It also identifies economic uncertainty as a risk to the availability and cost of capital. Management reported disclosure controls were effective and no material changes to internal control over financial reporting during the quarter.
- Margins and guidance: Revenue-based margins are not meaningful because the company had no revenue. The filing provides no quantified earnings or revenue guidance.
Investor verification points
- Confirm the intended issuer: the supplied filing is for Kintara Therapeutics, not the company named in the request metadata.
- Check subsequent filings for the status of Nasdaq listing compliance and any further equity financing or dilution.
- Verify actual REM-001 enrollment, grant reimbursements, and the remaining cash runway; the filing states additional funding is needed but does not provide a clear runway estimate.
- Review the full VAL-083 dataset and any disclosed consequences of suspending its development.
- Monitor the timing and terms of ATM or Lincoln Park share sales, and the amount of grant funding ultimately received.